Less than a month after informing the market of a slowdown caused by pandemic-related site closures in phase II studies with neonatal Fc receptor (FcRn)-targeting IMVT-1401, Immunovant Inc. said it’s voluntarily pausing dosing with the compound in thyroid eye disease (TED) in the study called Ascend Go-2 because of a worrisome physiological signal. The New York-based firm plans to investigate and, after seeking the FDA’s go-ahead on tweaks to the program, forge onward with development.
Transient gene editing of the herpes simplex virus type 1 using mRNA-based CRISPR was shown for the first time to be effective against herpetic stromal keratitis in mice and blocked HSV-1 replication in human corneas, Chinese researchers reported in the January 11, 2021, online edition of NatureBiotechnology.
RSS
